Clinical Trial Search

Primary: Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment — 23.7; 62.8; 29.1; 63.8 percentage…

Primary: Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome. — .30 proportion of subjects meeting endpoint — p=0.0154

Primary: Number of Participants With One or More Adverse Events Related to Study Drug — 6 Participants

Primary: Overall Clinical Success in Number and Size of Lesions as Measured by Photographic or Other Imaging Modality Depending on the Organ System Affected or Change in Affected…

Primary: Time to Confirmed Perceptible Pain Relief — NA; 15.7; 20.2; 23.2 minutes — p=<0.001

Primary: To Compare the Percentage of Subjects Who Achieved Significant Pain Relief Between the 3 Treatment Groups as Measured by a Visual Analog Pain Scale at 60 Minutes A…

Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg

Primary: Number of Participants Who Deliver With a Composite Adverse Birth Outcome — 60; 54 Participants

Primary: Overall Survival (OS) — 18.07; 14.09 Months — p=0.0020

Primary: Number of Participants With Complete Ulcer Closure — 74; 40 Participants

Primary: Change From Baseline in Basophils, Full Analysis Set — 0.014; 0.012; 0.013 10^9 cells/L

Primary: Clinical Outcome Responder Rate — 57; 11; 50; 46 Participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 42 Participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 78; 42 Participants

Primary: Numbers of Participants With Treatment Emergent Adverse Events and Laboratory Abnormalities — 95; 2 Participants